An observational study in Lung Cancer, Hepatocellular Carcinoma, sponsored by Hoffmann-La Roche. Recruiting at 92 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by Hoffmann-La Roche · Observational
This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's planned enrollment of 700 is above the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Hoffmann-La Roche is the lead sponsor of 2,061 studies on the registry; 85 are open to participants now.
Of its 319 completed or terminated interventional studies of FDA-regulated products, 239 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Participants diagnosed with early-stage NSCLC following complete resection and platinum-based chemotherapy with PD-L1 expression of >= 50% on TC, participants diagnosed with metastatic NSCLC with PD-L1 expression of ≥ 50% on TC who have not received prior systemic therapy for metastatic disease, participants diagnosed with ES-SCLC who have not previously been treated, and participants diagnosed with advanced or unresectable HCC who have not received prior systemic therapy.
Participants must have one of the following confirmed diagnoses for which atezolizumab is approved in the local SmPC:
Exclusion Criteria:
Participants diagnosed with early-stage NSCLC following complete resection and platinum-based chemotherapy with Programmed Cell-Death Ligand 1 (PD-L1) expression of \>= 50% on Tumor Cell (TC).
Drug: Atezolizumab
Participants diagnosed with metastatic NSCLC with PD-L1 expression of \>= 50% on TC who have not received prior systemic therapy for metastatic disease.
Drug: Atezolizumab
Participants diagnosed with ES-SCLC who have not previously been treated.
Drug: Atezolizumab
Participants diagnosed with advanced or unresectable HCC who have not received prior systemic therapy.
Drug: Atezolizumab
Atezolizumab will be administered at the discretion of the treating physician and independently of participation in this study.
Also known as: Tecentriq
Therapy Administration Satisfaction Questionnaire Subcutaneous (TASQ-SC) Score
Time frame: At Cycle 2 and Cycle 3 (each cycle duration/length is 3 weeks)
Overall Survival (OS)
Time frame: Index date up to approximately 3.5 years
OS at 2 Years
Time frame: After Index date up to 2 years
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) Score
Time frame: Baseline or Index date
Percentage of Participants With Adverse Events
Time frame: Up to approximately 3.5 years
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hoffmann-La Roche